Profil
Nuket Desem worked as a Senior Manager of Development & Regulatory Affairs at Alterity Therapeutics Ltd., Vice President of Clinical & Regulatory Affairs at Spinifex Pharmaceuticals Pty Ltd., Principal at CSL Ltd., Senior Associate at Kendle Pty Ltd., Development Director at Percheron Therapeutics Ltd., and Director of Clinical & Regulatory Affairs at Percheron Therapeutics Ltd.
and Paranta Biosciences Ltd.
Desem holds an MBA from Monash University and an undergraduate degree from LaTrobe University.
Ehemalige bekannte Positionen von Nuket Desem
| Unternehmen | Position | Ende |
|---|---|---|
| PERCHERON THERAPEUTICS LIMITED | Chief Tech/Sci/R&D Officer | 05.05.2023 |
| PERCHERON THERAPEUTICS LIMITED | Corporate Officer/Principal | 31.08.2010 |
| ALTERITY THERAPEUTICS LIMITED | General Counsel | - |
Paranta Biosciences Ltd.
 Paranta Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Paranta Biosciences Ltd. engages in the research and development of novel biotherapeutic. t develops PB01 (recombinant human follistatin-288) for the treatment of fibrotic and inflammatory diseases. The company was founded in 2011 and is headquartered in Richmond, Australia. | Chief Tech/Sci/R&D Officer | - |
| CSL LIMITED | Corporate Officer/Principal | - |
Ausbildung von Nuket Desem
| Monash University | Masters Business Admin |
| LaTrobe University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| CSL LIMITED | Health Technology |
| PERCHERON THERAPEUTICS LIMITED | Health Technology |
| ALTERITY THERAPEUTICS LIMITED | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Spinifex Pharmaceuticals Pty Ltd.
 Spinifex Pharmaceuticals Pty Ltd. Pharmaceuticals: MajorHealth Technology Spinifex Pharmaceuticals Pty Ltd. discovers and develops new drugs for the treatment and management of pain. The firm conducts medicinal chemistry and drug discovery activities, preclinical and early-phase clinical studies before seeking a partnership with pharmaceutical company to complete clinical development, file for regulatory approval, and carry out marketing activities. The company was founded in June 2005 and is headquartered in Preston, Australia. | Health Technology |
| Kendle Pty Ltd. | |
Paranta Biosciences Ltd.
Paranta Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Paranta Biosciences Ltd. engages in the research and development of novel biotherapeutic. t develops PB01 (recombinant human follistatin-288) for the treatment of fibrotic and inflammatory diseases. The company was founded in 2011 and is headquartered in Richmond, Australia. | Health Technology |
